 The Fourier trial showed a benefit of the PCSK9 inhibitor evalocumab over placebo with respect to cardiovascular outcomes in patients with cardiovascular disease. However, there were inconsistencies between the information in the clinical study report, CSR, and that in the 2017 primary trial results publication. An independent committee blindly re-adjudicated and restored the mortality data in the Fourier trial based on the information contained in the death narratives in the CSR. After re-adjudication, it was found that deaths of cardiac origin were numerically higher in the evalocumab group than in the placebo group, suggesting possible cardiac harm. At the time the trial was terminated early, a non-significantly higher risk of cardiovascular mortality was observed with evalocumab, which was numerically greater in our re-adjudication. Therefore, clinicians should be skeptical about prescribing evalocumab for patients with established atherosclerotic cardiovascular disease until further investigation has been conducted. This article was authored by Ken Bassett, James Wright, Leah Leachay, and others. We are article.tv, links in the description below.